{"id":9159,"date":"2023-07-27T18:44:49","date_gmt":"2023-07-27T16:44:49","guid":{"rendered":"https:\/\/www.afaf.asso.fr\/?p=9159"},"modified":"2023-07-31T13:57:11","modified_gmt":"2023-07-31T11:57:11","slug":"information-larimar-therapeutics","status":"publish","type":"post","link":"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/","title":{"rendered":"Information Larimar Therapeutics -communiqu\u00e9 de presse du 25 juillet 2023"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Larimar Therapeutics a annonc\u00e9 le 25\/07\/2023 que la Food and Drug Administration (FDA) des \u00c9tats-Unis a autoris\u00e9 l&#8217;essai de phase 2 d&#8217;exploration des doses de CTI-1601 (contr\u00f4l\u00e9 par placebo), \u00e0 passer \u00e0 une cohorte de 50 mg dans laquelle les participants atteints d\u2019ataxie de Friedreich recevront une dose quotidienne pendant les 14 premiers jours, puis tous les deux jours jusqu&#8217;au 28e jour.<br>En outre, la FDA a \u00e9galement autoris\u00e9 le lancement de l&#8217;essai OLE (open label extension) de Larimar. Les participants recevront 25 mg de CTI-1601 par jour.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><br>CTI-1601 est une th\u00e9rapie de remplacement prot\u00e9ique con\u00e7ue pour d\u00e9livrer de la frataxine dans les mitochondries des patients atteints, par l\u2019interm\u00e9diaire d\u2019une prot\u00e9ine transporteuse.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Vous trouverez le communiqu\u00e9 de presse sur le lien suivant (en anglais):<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"> <a href=\"https:\/\/investors.larimartx.com\/news-releases\/news-release-details\/larimar-therapeutics-receives-fda-clearance-proceed-50-mg-cohort?fbclid=IwAR09XTakfsv6YtdgAAWgmaPf8qwEDOBIQ1ow85c4DvTyKHwdBmPqufVIWzc_aem_ARW_8f224ChiwqzRe871XtpezegwNKrP6QOMHNVGZJV6bvfnunRDA-6RoK3qMqDZ6iw\" target=\"_blank\" rel=\"noreferrer noopener\">Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601\u2019s Phase 2 Friedreich&#8217;s Ataxia Trial and to Initiate Open Label Extension Trial &#8211; Larimar Therapeutics, Inc. (larimartx.com)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Larimar Therapeutics a annonc\u00e9 le 25\/07\/2023 que la Food and Drug Administration (FDA) des \u00c9tats-Unis a autoris\u00e9 l&#8217;essai de phase 2 d&#8217;exploration des doses de CTI-1601 (contr\u00f4l\u00e9 par placebo), \u00e0 passer \u00e0 une cohorte de 50 mg dans laquelle les participants atteints d\u2019ataxie de Friedreich recevront une dose quotidienne pendant les 14 premiers jours, puis [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":7805,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"ocean_front_end_style_editor":"no","ocean_post_layout":"","ocean_both_sidebars_style":"","ocean_both_sidebars_content_width":0,"ocean_both_sidebars_sidebars_width":0,"ocean_sidebar":"0","ocean_second_sidebar":"0","ocean_disable_margins":"enable","ocean_add_body_class":"","ocean_shortcode_before_top_bar":"","ocean_shortcode_after_top_bar":"","ocean_shortcode_before_header":"","ocean_shortcode_after_header":"","ocean_has_shortcode":"","ocean_shortcode_after_title":"","ocean_shortcode_before_footer_widgets":"","ocean_shortcode_after_footer_widgets":"","ocean_shortcode_before_footer_bottom":"","ocean_shortcode_after_footer_bottom":"","ocean_display_top_bar":"default","ocean_display_header":"default","ocean_header_style":"","ocean_center_header_left_menu":"0","ocean_custom_header_template":"0","ocean_custom_logo":0,"ocean_custom_retina_logo":0,"ocean_custom_logo_max_width":0,"ocean_custom_logo_tablet_max_width":0,"ocean_custom_logo_mobile_max_width":0,"ocean_custom_logo_max_height":0,"ocean_custom_logo_tablet_max_height":0,"ocean_custom_logo_mobile_max_height":0,"ocean_header_custom_menu":"0","ocean_menu_typo_font_family":"0","ocean_menu_typo_font_subset":"","ocean_menu_typo_font_size":0,"ocean_menu_typo_font_size_tablet":0,"ocean_menu_typo_font_size_mobile":0,"ocean_menu_typo_font_size_unit":"px","ocean_menu_typo_font_weight":"","ocean_menu_typo_font_weight_tablet":"","ocean_menu_typo_font_weight_mobile":"","ocean_menu_typo_transform":"","ocean_menu_typo_transform_tablet":"","ocean_menu_typo_transform_mobile":"","ocean_menu_typo_line_height":0,"ocean_menu_typo_line_height_tablet":0,"ocean_menu_typo_line_height_mobile":0,"ocean_menu_typo_line_height_unit":"","ocean_menu_typo_spacing":0,"ocean_menu_typo_spacing_tablet":0,"ocean_menu_typo_spacing_mobile":0,"ocean_menu_typo_spacing_unit":"","ocean_menu_link_color":"","ocean_menu_link_color_hover":"","ocean_menu_link_color_active":"","ocean_menu_link_background":"","ocean_menu_link_hover_background":"","ocean_menu_link_active_background":"","ocean_menu_social_links_bg":"","ocean_menu_social_hover_links_bg":"","ocean_menu_social_links_color":"","ocean_menu_social_hover_links_color":"","ocean_disable_title":"default","ocean_disable_heading":"default","ocean_post_title":"","ocean_post_subheading":"","ocean_post_title_style":"","ocean_post_title_background_color":"","ocean_post_title_background":0,"ocean_post_title_bg_image_position":"","ocean_post_title_bg_image_attachment":"","ocean_post_title_bg_image_repeat":"","ocean_post_title_bg_image_size":"","ocean_post_title_height":0,"ocean_post_title_bg_overlay":0.5,"ocean_post_title_bg_overlay_color":"","ocean_disable_breadcrumbs":"default","ocean_breadcrumbs_color":"","ocean_breadcrumbs_separator_color":"","ocean_breadcrumbs_links_color":"","ocean_breadcrumbs_links_hover_color":"","ocean_display_footer_widgets":"default","ocean_display_footer_bottom":"default","ocean_custom_footer_template":"0","ocean_post_oembed":"","ocean_post_self_hosted_media":"","ocean_post_video_embed":"","ocean_link_format":"","ocean_link_format_target":"self","ocean_quote_format":"","ocean_quote_format_link":"post","ocean_gallery_link_images":"off","ocean_gallery_id":[],"footnotes":""},"categories":[43],"tags":[],"class_list":["post-9159","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-informations_recherche","entry","has-media","owp-thumbs-layout-horizontal","owp-btn-normal","owp-tabs-layout-section","has-no-thumbnails"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Information Larimar Therapeutics -communiqu\u00e9 de presse du 25 juillet 2023 - Association Fran\u00e7aise Ataxie de Friedreich<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Information Larimar Therapeutics -communiqu\u00e9 de presse du 25 juillet 2023 - Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"og:description\" content=\"Larimar Therapeutics a annonc\u00e9 le 25\/07\/2023 que la Food and Drug Administration (FDA) des \u00c9tats-Unis a autoris\u00e9 l&#8217;essai de phase 2 d&#8217;exploration des doses de CTI-1601 (contr\u00f4l\u00e9 par placebo), \u00e0 passer \u00e0 une cohorte de 50 mg dans laquelle les participants atteints d\u2019ataxie de Friedreich recevront une dose quotidienne pendant les 14 premiers jours, puis [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-27T16:44:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-31T11:57:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3552\" \/>\n\t<meta property=\"og:image:height\" content=\"2365\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Caroline Gaboriau\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline Gaboriau\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/27\\\/information-larimar-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/27\\\/information-larimar-therapeutics\\\/\"},\"author\":{\"name\":\"Caroline Gaboriau\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/7366aa03c1779ab28140e42231ed7b28\"},\"headline\":\"Information Larimar Therapeutics -communiqu\u00e9 de presse du 25 juillet 2023\",\"datePublished\":\"2023-07-27T16:44:49+00:00\",\"dateModified\":\"2023-07-31T11:57:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/27\\\/information-larimar-therapeutics\\\/\"},\"wordCount\":170,\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/27\\\/information-larimar-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"articleSection\":[\"Informations sur la recherche\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/27\\\/information-larimar-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/27\\\/information-larimar-therapeutics\\\/\",\"name\":\"Information Larimar Therapeutics -communiqu\u00e9 de presse du 25 juillet 2023 - Association Fran\u00e7aise Ataxie de Friedreich\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/27\\\/information-larimar-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/27\\\/information-larimar-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"datePublished\":\"2023-07-27T16:44:49+00:00\",\"dateModified\":\"2023-07-31T11:57:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/27\\\/information-larimar-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/27\\\/information-larimar-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/27\\\/information-larimar-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"width\":3552,\"height\":2362},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/07\\\/27\\\/information-larimar-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Information Larimar Therapeutics -communiqu\u00e9 de presse du 25 juillet 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"description\":\"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.afaf.asso.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"width\":1181,\"height\":709,\"caption\":\"Association Fran\u00e7aise Ataxie de Friedreich\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/7366aa03c1779ab28140e42231ed7b28\",\"name\":\"Caroline Gaboriau\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g\",\"caption\":\"Caroline Gaboriau\"},\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/author\\\/caroline_gaboriau\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Information Larimar Therapeutics -communiqu\u00e9 de presse du 25 juillet 2023 - Association Fran\u00e7aise Ataxie de Friedreich","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/","og_locale":"fr_FR","og_type":"article","og_title":"Information Larimar Therapeutics -communiqu\u00e9 de presse du 25 juillet 2023 - Association Fran\u00e7aise Ataxie de Friedreich","og_description":"Larimar Therapeutics a annonc\u00e9 le 25\/07\/2023 que la Food and Drug Administration (FDA) des \u00c9tats-Unis a autoris\u00e9 l&#8217;essai de phase 2 d&#8217;exploration des doses de CTI-1601 (contr\u00f4l\u00e9 par placebo), \u00e0 passer \u00e0 une cohorte de 50 mg dans laquelle les participants atteints d\u2019ataxie de Friedreich recevront une dose quotidienne pendant les 14 premiers jours, puis [&hellip;]","og_url":"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/","og_site_name":"Association Fran\u00e7aise Ataxie de Friedreich","article_published_time":"2023-07-27T16:44:49+00:00","article_modified_time":"2023-07-31T11:57:11+00:00","og_image":[{"width":3552,"height":2365,"url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques.png","type":"image\/png"}],"author":"Caroline Gaboriau","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Caroline Gaboriau","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/"},"author":{"name":"Caroline Gaboriau","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/7366aa03c1779ab28140e42231ed7b28"},"headline":"Information Larimar Therapeutics -communiqu\u00e9 de presse du 25 juillet 2023","datePublished":"2023-07-27T16:44:49+00:00","dateModified":"2023-07-31T11:57:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/"},"wordCount":170,"publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","articleSection":["Informations sur la recherche"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/","url":"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/","name":"Information Larimar Therapeutics -communiqu\u00e9 de presse du 25 juillet 2023 - Association Fran\u00e7aise Ataxie de Friedreich","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","datePublished":"2023-07-27T16:44:49+00:00","dateModified":"2023-07-31T11:57:11+00:00","breadcrumb":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/#primaryimage","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","width":3552,"height":2362},{"@type":"BreadcrumbList","@id":"https:\/\/www.afaf.asso.fr\/2023\/07\/27\/information-larimar-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.afaf.asso.fr\/"},{"@type":"ListItem","position":2,"name":"Information Larimar Therapeutics -communiqu\u00e9 de presse du 25 juillet 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.afaf.asso.fr\/#website","url":"https:\/\/www.afaf.asso.fr\/","name":"Association Fran\u00e7aise Ataxie de Friedreich","description":"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich","publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.afaf.asso.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.afaf.asso.fr\/#organization","name":"Association Fran\u00e7aise Ataxie de Friedreich","url":"https:\/\/www.afaf.asso.fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","width":1181,"height":709,"caption":"Association Fran\u00e7aise Ataxie de Friedreich"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/7366aa03c1779ab28140e42231ed7b28","name":"Caroline Gaboriau","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g","caption":"Caroline Gaboriau"},"url":"https:\/\/www.afaf.asso.fr\/author\/caroline_gaboriau\/"}]}},"_links":{"self":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/9159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/comments?post=9159"}],"version-history":[{"count":0,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/9159\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media\/7805"}],"wp:attachment":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media?parent=9159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/categories?post=9159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/tags?post=9159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}